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ABSTRACT  
Basal cell carcinoma (BCC) is the most common cutaneous malignancy in humans. One of the 
most efficacious drugs used in the management of basal cell carcinoma BCC is the 
immunomodulator, imiquimod. However, imiquimod has physiochemical properties that limit its 
permeation to reach deeper, nodular tumour lesions. The use of microneedles may overcome such 
limitations and promote intradermal drug delivery. The current work evaluates the effectiveness 
of using an oscillating microneedle device Dermapen® either as a pre or post-treatment with 5% 
w/w imiquimod cream application to deliver the drug into the dermis. The effectiveness of 
microneedles to enhance the permeation of imiquimod was evaluated ex vivo using a Franz cell set 
up. After a 24-hour permeation experiment, sequential tape strips and vertical cross-sections of the 
porcine skin were collected and analysed using time-of-flight secondary ion mass spectrometry 
(ToF-SIMS). In addition, respective Franz cell components were analysed using high performance 
liquid chromatography (HPLC). Analysis of porcine skin cross-sections demonstrated limited 
dermal permeation of 5% w/w imiquimod cream. Similarly, limited dermal permeation was also 
seen when 5% w/w imiquimod cream was applied to the skin that was pre-treated with the 
Dermapen®, this is known as poke-and-patch. In contrast, when the formulation was applied first 
to the skin prior to Dermapen® application, this is known as patch-and-poke, we observed a 
significant increase in intradermal permeation of imiquimod. Such enhancement occurs 
immediately upon microneedle application, generating an intradermal depot that persists for up to 
24 hours. Intradermal colocalization of isostearic acid, an excipient in the cream, with imiquimod 
within microneedle channels was also demonstrated. However, such enhancement in intradermal 
delivery of imiquimod was not observed when the patch-and-poke strategy used a non-oscillating 
microneedle applicator, the DermastampTM. The current work highlights that using the patch-and-
poke approach with an oscillating microneedle pen may be a viable approach to improve the 
current treatment in BCC patients who would prefer a less invasive intervention relative to surgery.  
1. Introduction 
Basal cell carcinoma (BCC) is the most common skin cancer in humans 1.  Despite having a low 
tendency to metastasize, BCC may result in substantial peripheral tissue destruction if left 
untreated 2. The two most common BCC subtypes are superficial and nodular 3.  Superficial BCC 
generally manifests and proliferates parallel to the epidermis 4,5. On the other hand, nodular BCC 
typically resides deep within the papillary and reticular dermis 6. Despite the effectiveness of 
surgical interventions which display a 95% cure rate 7, accurate detection of tumour margins prior 
to surgery is pivotal in ensuring complete tumour resection. Such prerequisites are both time-
consuming and technical, which limits the use of such treatments 8. In addition, not all BCC 
patients are suitable for surgical intervention and some may opt for non-surgical treatment due to 
lower overall cost and better cosmetic outcomes 9-10. This is further corroborated by the findings 
of Tinelli et al who reported that patients generally preferred topical therapy over surgical 
intervention 11. One of the most efficacious drugs used in topical therapy for BCC is the 
immunomodulator, imiquimod 12.  
Recently, William et al reported that topical imiquimod therapy for BCC resulted in a cure rate 
significantly less than surgical intervention 13. The lower cure rate of imiquimod in treating BCC, 
particularly the nodular variant is due to the location of the tumour that resides deeper within the 
dermis 14. This tumour location provides an anatomical barrier for imiquimod to permeate in 
sufficient quantity to eradicate the tumour 15.  
One of the methods to improve the delivery of therapeutics for the treatment of BCC is via the use 
of microneedles. Microneedles are biomedical devices that consist of arrays of fine needles with 
lengths ranging between 250 and 1000 µm. Upon application to the skin, these devices generate 
transient channels that provide a route across the stratum corneum into the deeper layers of the 
skin 16. The application of microneedle-based drug delivery for the management of BCC was 
pioneered by Donnelly et al 17. Donnelly et al demonstrated that microneedles enhanced the 
localised delivery of aminolaevulinic acid into the skin for BCC treatment. Further to this Naguib 
et al. demonstrated, via a murine model, the feasibility of using solid microneedles to enhance the 
intradermal delivery of 5-fluorouracil to treat skin tumours. Following these studies, various 
groups have explored different microneedle designs to deliver a range of anticancer agents such as 
methyl aminolevulinic acid (MAL) 18, meso-tetra(N-methyl-4-pyridyl)orphinetetratosylate (TMP) 
19,  and itraconazole 20.   
Detailed analysis of the dermal distribution of pharmaceuticals within the skin strata is paramount 
in order to evaluate the permeation enhancement effect conferred by microneedles for targeted 
skin delivery. Traditionally, chromatographic analysis (e.g. high-performance liquid 
chromatography, HPLC) is frequently implemented in microneedle permeation studies in order to 
evaluate the delivery of drugs into and across the skin. However, this analytical method is 
dependent on efficient drug extraction and effective column separation from co-extracted 
endogenous components of the skin. Furthermore, the tissue manipulation steps and extraction 
procedures lead to the loss of valuable spatial information regarding drug localisation within the 
skin tissue 21. In order to overcome this limitation, microneedle permeation studies frequently use 
fluorescently-tagged molecules in order to track their distribution within the skin 22. This method 
of tracking dermal distribution can be achieved via the use of confocal laser scanning microscopy 
(CLSM). CLSM utilises point illumination via the use focused laser beam that is rastered across 
the sample of interest. The emitted fluorescence from the in-focus plane is passed through a pinhole 
onto a detector, which the measures the fluorescence from the site of analysis. Any out-of-focus 
fluorescence is blocked by the pinhole, which is said to be confocal with the focal point of the 
objective lens. CLSM has been used to tracked the permeation of compounds delivered using 
microneedle-based delivery systems 23–25. Although this approach allows the experimenters to 
track drug localisation within the skin, the use of fluorescent tagging with this method alters the 
physiochemical properties of molecules leading to erroneous estimation of drug distribution in 
biological tissues 26. In addition, the need for different fluorescent tagging to track the dermal 
distribution of multiple molecules complicates the method even further. Hence, there is a clear 
need for advanced analytical techniques to be utilised in the field of microneedle research to allow 
researchers to track drug distribution within skin tissues in a label-free manner. 
Some of the techniques that offer label-free imaging of dermal drug distribution include confocal 
Raman microscopy and stimulated Raman scattering microscopy. These techniques has been used 
to visualise the dermal distribution of several pharmaceuticals such as 5-fluorouracil 27, ketoprofen 
28, and terbinafine 28. Although these methods offer experimenters the ability to visualise dermal 
drug distribution in a label-free manner, the Raman signal is normally a weak. This necessitates 
that the molecule of interest should be present at sufficient concentration to allow detection. In 
addition, the drug molecules also need to possess Raman active chemical groups that are different 
from native skin biomolecules to permit differentiation and detection. Another issue associated 
with Raman-based imaging is the high level of autofluorescence from biological tissue which can 
mask the weak Raman signal thus limiting the utility of these techniques to map dermal drug  
distribution 29. 
Time-of-flight secondary ion mass spectrometry (ToF-SIMS) on the other hand is a powerful 
surface analytical technique that confers excellent mass and spatial resolution along with chemical 
sensitivity 30,31. Analysis of samples using ToF-SIMS allows chemical mapping of the distribution 
of a compound of interest by tracking the mass-to-charge ratio (m/z) of specific molecular ions 
from the mass spectra. This analytical approach allows us to track the distribution of compounds, 
both exogenous and endogenous, within a biological milieu in a label-free manner. Such analytical 
power conferred by ToF-SIMS has led to the use of the technique to analyse a range of biological 
materials such as insulin and even cancerous tissue  32–37. In addition, the ability of the instrument 
to track the topical permeation of pharmaceuticals and cosmeceuticals such as chlorhexidine 38,39, 
ascorbic acid 21, dihydroquercetin 40, fatty acids 41,  carvacrol 42 and roflumilast 43 highlights the 
value of the technique in skin research. Despite the powerful analytical capability offered by this 
form of mass spectrometry imaging, the utility of ToF-SIMS in evaluating the effectiveness of 
microneedle-based drug delivery system has yet to be fully demonstrated. 
A previous study demonstrated the limited permeation of imiquimod into the skin when the drug 
is administered as a topical cream 44. This work also demonstrated that solid microneedles provided 
a solution to deliver imiquimod beyond the stratum corneum and into the viable epidermis. 
However, such delivery depth was not sufficient to reach the dermal depth in which nodular BCC 
typically resides. In the present work, we explore further the application of solid microneedles as 
a physical permeation enhancement strategy to deliver imiquimod deeper into the dermis for BCC 
treatment. In addition, the microneedle system should deliver imiquimod to a depth of 
approximately 400 µm below the skin surface which is the target region in which nodular BCC 
typically manifests 13. The current study highlights that the approach in which microneedles are 
used in combination with an imiquimod cream, can lead to the successful intradermal delivery of 
imiquimod. The concept of using a patch-and-poke strategy with solid microneedles was initially 
conceptualized in a review published by McCaffrey et al. as a method to deliver genes into the 
skin 45. Patch-and-poke is defined at the application of formulations onto the skin prior to solid 
microneedle application. However, research on the effectiveness of the patch-and-poke approach 
using solid microneedle is limited. This is because research on solid microneedles focuses mostly 
on a poke-and-patch strategy to deliver drug into or across the skin. Furthermore, using the poke-
and-patch strategy results in the generation of hydrophilic/aqueous microneedle channels post 
application that act as a barrier to the permeation of hydrophobic drugs into the skin 46,47. 
Therefore, there is a lacuna in the knowledge about the effectiveness of using the patch-and-poke 
approach with solid microneedles.  
In this work, it is demonstrated that a patch-and-poke strategy is more effective in delivering 
imiquimod intradermally than the conventional poke-and-patch approach. This work also 
demonstrated that microneedle oscillation during application plays an important role in the  
effective intradermal delivery of imiquimod using the patch-and-poke strategy.   
2. Experimental section 
2.1. Materials  
Imiquimod was purchased from Cayman Chemicals, USA. Aldara™ topical cream (5% w/w 
imiquimiod), MEDA Company, Sweden was purchased from Manor pharmacy, UK. Dermapen®, 
which is a microneedling pen, was purchased from ZJchao, China. The microneedles on the 
Dermapen® had a tapered conical structure. The microneedle had a base diameter of 370 µm with 
a tip radius of 53.4o. The distance between microneedles (pitch) was 620 µm. Microneedles were 
arranged in rows which formed an overall circular area. The Dermapen® has five different 
oscillation speeds- 8000, 10000, 12000, 14000 and 16000 RPM. In addition, the needle length 
could be adjusted between 250-1500 µm. For the purpose of the permeation study, we selected a 
microneedle length 1000 µm and an oscillation speed of 8000 RPM. During application, the pen 
was held by one hand with gentle pressure while the hand was used to hold the skin in place. The 
DermastampTM which was a microneedle stamp, was purchased from Teoxy Beauty, Wuhan, 
China. The microneedles on the DermastampTM also had a tapered conical structure. The 
microneedle had a base diameter of 210 µm with a tip radius of 22.8o. The distance between 
microneedles (pitch) was 1050 µm. Microneedles were arranged in an annular fashion which 
formed an overall circular area. The DermastampTM had no oscillating function and the needle 
length of the Dermastamp used was fixed to 1000 µm. During application, the DermastampTM was 
held by one hand with and applied by one swift stamping motion with gentle pressure. Sodium 
acetate was purchased from Sigma-Aldrich, UK. Acetonitrile (HPLC grade) and glacial acetic acid 
were obtained from Fisher Scientific, UK. Teepol solution (Multipurpose detergent) was ordered 
from Scientific Laboratory Supplies, UK. D-Squame standard sampling discs (adhesive discs) 
were ordered from Cuderm corporation, USA. OCT media was obtained from VWR International 
Ltd. Belgium. Deionised water was obtained from an ELGA reservoir, PURELAB® Ultra, ELGA, 
UK. All reagents were of analytical grade, unless otherwise stated. Ex vivo porcine skin was used 
to investigate the permeation of imiquimod due to the similarities in histology, thickness and 
permeability to human skin 48. Skin samples were prepared from ears of six month old pigs 
obtained from a local abattoir prior to steam cleaning. Full skin thickness was used to prevent 
altering the skin biomechanical properties which may lead to over-penetration of the microneedles 
into the skin 49. The porcine skin samples were stored at -20 °C until analysis. The integrity of the 
skin samples prepared via this method was assessed by electrical resistance, using the method and 
guidelines described by Davies et al using EVOM2 Voltohmmeter (World Precision Instruments, 
U.S.A). Only skin that produced an electrical resistance reading of greater than  
10 kΩ was used. 50. 
2.2.1. Permeation study of 5% w/w imiquimod cream through porcine skin 
Imiquimod dermal permeation with and without microneedle treatment was evaluated ex vivo 
using a Franz-type diffusion cell. Prior to the permeation study, skin samples were defrosted for 
at least an hour at room temperature. The skin was trimmed into small pieces according to the 
surface area of the donor chamber of the Franz diffusion cell (Soham Scientific, Cambridgeshire, 
UK). The trimmed skin samples were equilibrated by placing them above the receptor 
compartment for 15 minutes prior to skin treatment. The Franz cells used in this study has a 
receptor compartment volume of 3 ml. 
The porcine skins were subjected to the following treatment modalities: i) application of 20 mg 
Aldara™ cream alone ii) application of 1000 µm microneedles to the skin as a pre-treatment using 
Dermapen® followed by 20 mg Aldara™ cream. 1000 µm refers to the length of the microneedles. 
This is known as the poke-and-patch approach. 12-microneedle array cartridges were used for this 
treatment. iii)  Application of 20 mg Aldara™ cream followed by 1000 µm microneedle treatment 
using Dermapen®. This is known as the patch-and-poke approach. Either a 12-microneedle or a 
36-microneedle array cartridge were used for this treatment. All the arrays used in the microneedle 
treatment groups have similar surface area of application which is 0.64 cm2 
Next, the porcine skins were placed on top of the receptor compartment filled with 3 ml of degassed  
100 mM acetate buffer pH 3.7. This buffer was selected as the receptor phase in order to maintain 
a sink condition throughout the permeation study. This is due to the insolubility of imiquimod at 
neutral or basic pH values. Various groups have reported the use of acetate buffer pH 3.7 as the 
receptor phase in imiquimod permeation studies 51–53. The skin was then secured between the donor 
and receptor compartment of the diffusion cell using a metal clamp, with the stratum corneum side 
facing the donor compartment. Upon assembling the Franz diffusion cell, the permeation 
experiment was conducted over a period of 24 hours in a thermostatically controlled water bath 
set at 36.5 oC. 
2.2.2 Quantification of imiquimod post-permeation study 
After a 24-hour permeation experiment, the excess cream was removed and collected from the 
skin surface by careful application of sponges soaked with 3% v/v Teepol® solution. The sponges 
were pooled for imiquimod HPLC analysis as a total skin wash. Any formulation which might 
have spread to the donor chamber was collected by the sponges and stored for imiquimod analysis 
by HPLC as a donor chamber wash. Upon removing excess formulation from the skin surface, 15 
sequential tape strips were collected from the skin as detailed in Section 2.2.4.  
The amount of imiquimod from the different Franz cell elements (skin wash, donor chamber wash, 
pooled tape strips and remaining skin after tape stripping) were extracted by the addition of 5, 5, 
10 and 5 mL of methanol extraction mixture (Methanol 70%: Acetate Buffer pH 3.7 100 mM 30%) 
respectively using a previously reported method 54. Samples were then vortexed for 1 minute and 
sonicated for 30 minutes before being left overnight. Subsequently, samples were vortexed again 
and sonicated for a further 30 minutes. 1 ml of the extracts were collected and spiked with 100 µl 
of 100 µg/ml propranolol as an internal standard. The samples were then filtered through 0.22 µm 
membrane. For the receptor fluid, 1 ml of the solution from each Franz cells were collected and 
spiked with 100 µl of 100 µg/ml propranolol as an internal standard before being filtered through 
0.22 µm membrane. HPLC analysis was carried out using an Agilent 1100 series instrument 
(Agilent Technologies, Germany) equipped with degasser, quaternary pump, column thermostat, 
autosampler and UV detector. System control and data acquisition were performed using 
Chemostation software. The details of the HPLC chromatographic conditions are as follow: 
column C18 (150 × 4.6 mm) ACE3/ACE-HPLC Hichrom Limited, UK. The mobile phase 
composition for analysis of extracts from skin wash, donor chamber wash, pooled tape strips and 
remaining skin consists of 10 mM acetate buffer: acetonitrile (79:21). Whilst, the mobile phase 
composition for analysis of receptor fluid consists of 10 mM acetate buffer: acetonitrile (70:30). 
The system operated at a flow rate of 1.0 mL/minute, UV detection at λ max=226 nm, injection 
volume of 40 µL and column temperature of 25 °C.   
2.2.3 Tape stripping and cryo-sectioning of porcine skin post-permeation experiment for ToF-
SIMS analysis. 
After 24 hours, the skins were detached from the Franz diffusion cells. Excess AldaraTM cream 
was removed. 15 sequential tape strips were collected for each skin samples. Sequential removal 
of corneocytes was judged by the resistance felt during the stripping step and the change in opacity 
of the tape post stripping.  The skin was rotated 180° for each tape strip. This ensures that the tape 
stripping would not result in premature removal of the whole stratum corneum during tape 
stripping. All tape strips collected were stored in a freezer at -20 °C until analysis. 
In order to measure the depth of imiquimod permeation into the skin, the permeation experiments 
were repeated as described above in Section 2.2.2. After the permeation study, excess formulation 
was removed and a 1 cm x 1 cm of each microneedle application site was fresh frozen with liquid 
nitrogen. Skin cross-sectioning was performed using a cryostat (Leica CM3050 S Research 
Cryostat, UK). The skin slices were then thaw mounted on a glass slides and stored at -20 oC prior 
to ToF-SIMS analysis. 
2.2.4 ToF-SIMS analysis 
ToF-SIMS was used to analyse individual tape strips and cryo-sectioned porcine skin samples. 
ToF-SIMS analysis was performed using a ToF-SIMS IV instrument (IONTOF, GmbH) with a 
Bi3
+ cluster source. A primary ion energy of 25 KeV was used, the primary ion dose was preserved 
below 1 × 1012 per cm2 to ensure static conditions. Pulsed target current of approximately 0.3 pA, 
and post-acceleration energy of 10 keV were employed throughout the sample analysis. The mass 
resolution for the instrument was 7000 at m/z 28. The scanned area of the tape strips samples was 
(4 mm × 4 mm) encompassing the skin area exposed to Aldara™ cream during Franz cell diffusion 
experiments. Whilst, an analysis area of (1.5 mm x 3 mm) was employed for the skin cross-
sections. Both sample types were analysed at a resolution of 100 pixels/mm. An ion representing 
biological material and therefore indicative of skin (skin marker) was identified as CH4N
+ and was 
used to threshold the data sets from tape strips. CH4N
+ is a common fragment observed in organic 
materials such as biological specimens. Therefore, this secondary ion was used to track the 
presence of corneocyte extracted on the tape strips. The data was reconstructed to remove the data 
from the adhesive tape material found between the fissures in the stripped skin and therefore the 
data was only analysed from the skin material. Following this, each image of the individual tape 
strip (4 mm × 4 mm) was divided into four smaller data sets of (2 mm × 2 mm) which results in 
four repeats (n = 4) for each sample and their intensities were normalised to the total ion intensity. 
All ToF-SIMS data were acquired in positive spectra as this gave the best ionization intensity for 
imiquimod based on our previous work 44. In addition, pure imiquimod, pure isostearic acid and 
Aldara™ cream reference spectra were obtained by analysing the pure drug, pure fatty acid and 
the cream on silicon wafers using ToF-SIMS. 
2.2.5 Understanding the effect of vibration of Dermapen® on the intradermal permeation of 
imiquimod 
One of the features of the Dermapen® is the ability of the device to vibrate the microneedles at the 
tip of the device. In order to understand the role of oscillation on the intradermal delivery of 
imiquimod into the skin, the permeation study was repeated as detailed in Section 2.2.2. However, 
porcine skins were subjected to the following treatment modalities: i) Application of 20 mg 
AldaraTM cream followed by 1000 µm microneedle treatment using Dermapen®. A 36-microneedle 
array cartridge was used for this treatment ii) Application of 20 mg AldaraTM cream followed by 
1000 µm microneedle treatment using a non-vibrating DermastampTM. The DermastampTM 
consists of 40-microneedle array per stamp. The DermastampTM was similar to the Dermapen® in 
terms of microneedle length used (which is 1000 µm) and the material used to manufacture the 
needle, which was stainless steel. The only main difference was that the DermastampTM did not 
have any vibration function. After a 24-hour permeation study, the skin samples were cryo-
sectioned and analysed by ToF-SIMS using the same conditions outlined in Section 2.2.5. In 
addition, a time point study (0, 1, 6, 12 and 24 hours) was conducted to evaluate how the dermal 
distribution of imiquimod changes over the course of 24 hours with the patch-and-poke approach 
using the Dermapen®. 
3. Results and discussion 
3.1. Skin insertion and dye binding study 
An ex vivo skin insertion study was conducted to establish the microneedle length needed to reach 
the skin strata where nodular BCC typically resides. From the supplementary data, Figure S1, it 
can be seen that when the length of Dermapen was adjusted to 1000 µm, an insertion depth of 
approximately 600 µm was observed. Such penetration depth is sufficient to reach beyond the 
epidermis layer and into the dermis layers. As nodular BCC typically manifests from the stratum 
basale at the dermoepidermal junction and grows deeper into the dermis, this suggests that 
adjusting the Dermapen® to 1000 µm would provide sufficient penetration to reach nodular BCC 
tumours 55. Therefore, guided by the skin insertion study data, we selected the 1000 µm length 
microneedles (Dermapen®) for the skin permeation study.  
3.2 HPLC analysis of imiquimod from Franz cell components post-permeation study. 
HPLC analysis was performed in order to quantify the amount of imiquimod that has remained or 
permeated into respective Franz cell compartments over the course of the permeation study. The 
mean amount of imiquimod (µg) recovered from the various Franz cell components following the 
24-hour permeation study is shown in Figure 1. The amount of imiquimod extracted from the 
applied dose from cream alone was highest in the skin wash relative to other Franz cell 
components. This suggests that when imiquimod is delivered as a topical cream, the drug displayed 
limited permeation into the skin. Such findings agree with previous work that showed that 
application of imiquimod as a topical cream resulted in the majority of the dose being recovered 
from the skin surface 44. However, the amount of imiquimod recovered contradicts the finding by 
Stein et al, who found that only 19% of the applied AldaraTM cream remained on the skin surface 
highlighting sufficient dermal permeation of imiquimod 56. Such enhanced permeation reported by 
Stein and co-worker is likely due to the use of murine skin which is more permeable and thinner 
in comparison to human and porcine skin 57. 
 
Figure 1 HPLC analysis of the mean amount of imiquimod recovered from the different Franz cell 
components (donor chamber wash, skin wash, tape strips, remaining skin and receptor fluid) post-
permeation study. Data is presented as the mean ± SD (n = 6). The inset details the amount of 
imiquimod that has permeated into (b) tape strips (c) remaining skin and (d) receptor fluid. 
Differences were calculated using one-way ANOVA, followed by Tukey’s post hoc test, and 
deemed significant at p<0.05. n.s = not statistically significant at p>0.05 
 
One of the ways to circumvent the limited dermal permeation of imiquimod is to utilise a physical 
permeation enhancer such as microneedles to promote the delivery of the drug into the skin. Thus, 
in this study, we utilised a microneedling device, Dermapen® in order to enhanced imiquimod 
delivery into the skin. One of the earliest and simplest microneedle-based approaches to promote 
intradermal drug delivery is via the poke-and-patch method 46. However, when we conducted an 
ex vivo skin permeation study, we observed that the delivery profile of imiquimod with the poke-
and-patch approach was similar to topical cream application as shown in Figure 1.  
One of the possible explanations for the similar permeation profile of imiquimod into and across 
ex vivo skin between these two strategies (cream alone vs poke-and-patch) is due to the formation 
of hydrophilic microneedle channels from the outflow of dermal interstitial fluid upon microneedle 
application 46,47. Such channels may act as a barrier for the effective permeation of a hydrophobic 
drug such as imiquimod 58. Therefore, we also investigated if the application of topical AldaraTM 
cream (5% w/w imiquimod) followed by microneedling, a patch-and-poke approach, as an 
alternative strategy to improve the delivery of imiquimod into the skin. When the ex vivo skin 
permeation study was carried out using the patch-and-poke strategy, we observed a decrease in the 
amount of imiquimod recovered from the skin wash. This was statistically significant when the 
patch-and-poke approach used a 36-needle cartridge. 
Although not statistically significant, the HPLC analysis of imiquimod extracted from remaining 
skin showed an increasing trend in the amount of imiquimod delivered into the skin with the patch-
and-poke approach in comparison to the poke-and-patch approach. However, the difference in the 
amount delivered across the skin was most prominent from the analysis of receptor fluid. Analysis 
of receptor fluid indicates an increase in the amount of imiquimod delivered into and across the 
skin. However, such differences were only statistically significant when the  
patch-and-poke approach was adopted using the 36-microneedle array Dermapen®.  
In addition, we have established that sink condition were maintained throughout our study as will 
be described. The saturation solubility of imiquimod, which is a weak base, in the receptor 
compartment, acetate buffer 100 mM, has been reported by De Paula et al is 1360.2 (μg/mL) at 
pH 4.0 54. Therefore, as we used a lower pH acetate buffer, pH 3.7, which has been used in by 
other investigators 51–53, we predicted that the solubility of the drug at pH 3.7 would be comparable 
if not higher than that reported by De Paula et al.  Data for the receptor fluid that has been converted 
into μg/mL in the Supplementary Information (Figure S2) indicates that the highest concentration 
detected was on average 48.7 µg/ml. This indicates that after 24 hours, the highest average 
concentration imiquimod within the receptor fluid was 3% of its saturation solubility concentration 
reported. Ng et al have indicated that in order for sink conditions to be maintained, the penetrant 
concentrations in the receptor solution should not be more than 10% of their saturation solubility 
concentration 59. Based on this information, we can confirm that sink conditions were indeed 
maintained throughout the permeation study. 
The increase in amount of imiquimod delivered across into the receptor fluid may be attributed to 
the enhanced amount of imiquimod delivered into the dermis using the patch and poke approach. 
Imiquimod is known to have low aqueous solubility such as in the interstitial fluid within the 
dermal microenvironment, but displays higher solubility in acidic pH due the molecule being a 
weak base 54. Based on the physiochemical property of the drug, it is likely that imiquimod 
delivered into the dermis may have partitioned into the acidic acetate buffer within the receptor 
solution over time as the drug has higher solubility in the acidic buffer. In addition, it is worth 
noting that the dermis receives a rich blood supply that is derived from the hypodermis. Therefore, 
it is postulated that any drug that reaches this layer of the skin, after traversing the tortuous 
epidermal layers, has the potential to be rapidly absorbed into the systemic circulation 55. Based 
on Figure 1 (c) and (d), it can be inferred that the patch-and-poke strategy may result in improved 
delivery into the dermis which is target region for nodular BCC. The partitioning of the drug into 
the receptor fluid may provide some indication of potential systemic exposure. Based on Figure 1 
it can be inferred that although the patch-and-poke strategy may result in improved delivery into 
the dermis, such mode of delivery may lead to increased systemic exposure of imiquimod which 
could result is side effects such as flu-like symptoms 60. However, such mode of delivery may lead 
to unwanted systemic exposure. Therefore, in order to limit the likelihood of such side effects 
arising, it could be suggested that reducing dosing frequency for the patch-and-poke strategy 
relative to the dosing frequency of AldaraTM application alone may mitigate the likelihood of such 









3.3 ToF-SIMS analysis of tape strips post-permeation study 
Despite HPLC analysis of different Franz cell component providing quantitative results, the 
method does not confer any information detailing imiquimod distribution within individual layers 
of skin. Therefore, an additional analytical technique was used to provide spatial information 
regarding imiquimod permeation. Analysis of samples using ToF-SIMS allows a chemical map of 
the distribution of a compound of interest to be acquired as well as providing information on how 
such distribution changes with depth. In previous work, it has been found that the permeation of 
the imiquimod across the skin could be tracked by monitoring the molecular ion C14H17N4
+ 44. ToF-
SIMS secondary ion images of the analysed tape stripped area, which represents the exposed area 
of the skin to Aldara™ cream during Franz cell diffusion experiment, are illustrated in  
Figure 2. An ion representative of skin tissue (CH4N
+) and a diagnostic imiquimod ion 
(C14H17N4
+) ion images for tape strips no. 6 are shown in Figure 2 (a). It was apparent that the 
signal from the skin marker (CH4N
+) was much lower in the two top ion images. However, should 
there be a reduction or increase in the ions collected, each ToF-SIMS image collected is normalised 
to the total ion collected. As all the ion images collected have been scaled to the same value as 
shown with scale bars, we attributed the signal reduction from the skin marker (CH4N
+) for the 
two top ion images is due to biological variation as the porcine skin used is from different pigs’ 
ears. 
 
Figure 2. (a) ToF-SIMS 4 mm × 4 mm secondary ion distribution maps on tape strip surfaces. 
The scale bar represents 1 mm, and the images have been normalized to the total ion image. The 
distribution maps are from tape strip no. 6, showing the distribution of the imiquimod molecular 
ion (C14H17N4
+), and biological marker for corneocytes (CH4N
+) (b) ToF-SIMS exported peak 
intensities (normalized to total ion intensity) for imiquimod molecular ion peak as a function of 
increasing tape strip number from porcine skin. The skin was either treated with AldaraTM cream 
only, pre-treated with microneedles (1000 µm) before AldaraTM cream application or treated with 
microneedles (1000 µm) of different array size after cream application. Data are expressed as 
mean ± SEM for n=12 analytical repeats. MN-refers to microneedles, Differences were 
calculated using one-way ANOVA, followed by Tukey’s post hoc test, and deemed significant at 
p<0.05 
 Figure 2 (b) highlights how imiquimod ion intensity changes with stratum corneum depth as a 
function of tape strip number. The decrease in permeation of imiquimod from tape strips no. 2 to 
no. 12 is due to an increase in water content with stratum corneum depth which limits the 
permeation of imiquimod 61. The poor water solubility and lipophilicity of imiquimod resulted in 
limited dermal permeation when the drug is applied to the skin as a topical cream. Specifically, as 
imiquimod is a lipophilic molecule, when the drug is only applied as a topical cream it is likely 
that the molecule mostly permeates from the cream and into the superficial layer of the stratum 
corneum. As the superficial layer of the stratum corneum are known to be lipid rich, imiquimod 
would partition into this lipid matrix and remain there relative to permeating deeper into the skin. 
This may serve as an explanation for the higher imiquimod ion intensity observed from tape strips 
obtained from skin samples treated with AldaraTM cream alone relative to skin subjected to 
microneedle application. 
In contrast, it can be seen from Figure 2 (b) that perforating the skin with microneedles either 
before or after cream application results in a decrease in the measured imiquimod ion intensity 
from ToF-SIMS analysed tape strips in comparison to tape strips from skin samples treated with 
AldaraTM cream alone. This finding agrees with the trend observed from the HPLC results in 
Figure 1 (b) that showed lower imiquimod concentration in the pooled tape strips from skin 
samples subjected to microneedle perforation relative to AldaraTM cream only treated skins. This 
observation may be attributed to the generation of microneedle channels within the stratum 
corneum with microneedle application. When the microneedle was applied as a pre-treatment 
using the 12 arrays via the poke-and-patch strategy, the stratum corneum is now perforated with 
aqueous microneedle channels. As the drug is poorly water soluble these aqueous channels may 
hinder the permeation of the drug into the stratum corneum resulting in lower imiquimod ion 
intensity relative to AldaraTM cream. Without any aqueous microneedle channels in the cream only 
treated group, the drug will be able to partition and remain in the lipid rich matrix of the stratum 
corneum. However, when the microneedle was applied after cream application using either the 12 
or 36 arrays, via the patch-and-poke strategy we also observed lower imiquimod ion intensity 
relative to AldaraTM cream. In this instance, the microneedle application is now mechanically 
inserting the drug across the stratum corneum and directly into the epidermis and dermis. 
Therefore, there will be less cream available on the skin surface as evidenced from the HPLC data 
in Figure 1 (a) for skin wash. As there is less cream on the skin surface, there will now be less 
drug to partition from the skin surface and into the stratum corneum resulting in lower imiquimod 
ion intensity relative to AldaraTM cream. 
On the other hand, the current finding contradicts our previous report that showed higher 
imiquimod ion intensity from ToF-SIMS analysed tape strips obtained from the poke-and-patch 
approach relative to topical cream application alone 44. In this work, a shorter microneedle length 
(250 µm) was employed while 1000 µm was used in this study. The shorter needles used in the 
previous work may generate shallower microneedle channels that remained mostly within the 
viable epidermis layer. These shallower microneedle pores are more likely to promote the 
permeation of imiquimod into the superficial layer of the skin rather than flowing deeper into the 
dermis. These shallower drug-filled microneedle channels may act as focal points for the drug to 
radiate out to surrounding corneocytes, resulting in higher imiquimod intensity when a shorter 
microneedle length is used with the poke-and-patch approach relative to topical cream alone. 
3.4 ToF-SIMS Analysis of Skin Cross-sections 
 
3.4.1 Effect of microneedle pre-treatment “poke-and-patch” versus post-treatment “patch-and-
poke” on the delivery of imiquimod. 
 
It was apparent from ToF-SIMS analysis of tape strips as shown in Figure 2 (b), that using either 
the poke-and-patch or patch-and-poke approach, we observed a similar trend in the permeation of 
imiquimod through the stratum corneum. This suggests that both microneedle application 
strategies, either before or after cream application may not influence the permeation of imiquimod 
through the stratum corneum. In order to investigate if the two solid microneedle application 
strategies may influence the intradermal delivery of imiquimod deeper into the skin, we employed 
ToF-SIMS analysis of skin cross-sections in addition to tape strip analysis. Understanding the 
spatial distribution of molecular species is paramount in elucidating the effectiveness of drug 
delivery systems within a biological tissue. Conventional liquid chromatography mass 
spectrometry (LC-MS) is traditionally employed to understand the effectiveness of a drug delivery 
strategy, however the extraction process employed leads to loss in spatial information 62. ToF-
SIMS has the capability to simultaneously map molecular ion of the dosed compound in tandem 
with the native fragment ions from skin tissue 38. Examples of ion signals used to distinguish 
respective skin strata are C5H15NPO4
+ (a fragment ion for phosphatidylcholine) and C17H32N
+ (a 
fragment ion for ceramide) 43. The stratum corneum displays high levels of ceramide whilst being 
devoid of phospholipids 63. Therefore, phosphatidylcholine ion fragments were used to map the 
viable epidermis and dermis while ceramide fragment ions were used to identify the stratum 
corneum.  
From Figure 3, it is evident that there is limited availability of imiquimod within deeper skin layers 
when applied either through topical cream alone (i) or via the poke-and-patch (ii) approach. 
However, when Aldara™ is applied via the patch-and-poke approach in Figure 3 (iii) and (iv), we 
observed enhanced imiquimod delivery into the dermis. This observation agrees with the trend 
observed from the HPLC analysis from Figure 1 (c) that shows an increase in imiquimod 
concentration in the skin with the patch-and-poke approach using 36-needle array Dermapen®. In 
addition, the delivered drug is localised within microchannels formed during microneedle 
insertion. Typically nodular BCC presents 400 µm below the skin surface 13. The ToF-SIMS 
analysis of skin cross-sections from Figure 3 suggest that the patch-and-poke approach may be a 
suitable strategy to enable enhanced imiquimod delivery into the dermis for the treatment of 
nodular BCC. 
It has been demonstrated previously that ToF-SIMS can chemically image drug permeation 
through microneedle channels in the stratum corneum and upper epidermis 44 . However, these 
studies adopted a poke-and-patch approach that showed localisation of imiquimod within the 
stratum corneum which agrees with the current findings 44. One of the possible explanations for 
the limited drug permeation with the poke-and-patch approach is the viscoelastic property of the 
skin that causes some regions of the skin to recoil and close over time after microneedle 
application. In some instances, the closure can be as rapid as 5 minutes 64,65.  This rapid closure of 
microneedle pores may limit dermal permeation of imiquimod via the poke and patch approach. 
Additionally, perforating the skin with microneedles prior to cream application promotes the flow 
of more interstitial fluid into the microneedle channels.  This results in the formation of hydrophilic 
pores that act as a barrier to the entry of hydrophobic drugs, such as imiquimod, deeper into the 
dermis 46,47.  This phenomenon does not affect the intradermal delivery of imiquimod using the 
patch-and-poke approach, as the drug is mechanically driven into the skin during repeated 
microneedle insertion circumventing the effect of microneedle pore closure. 
 
Figure 3. ToF-SIMS secondary ion distribution map of skin cross sections from porcine skin that 
were treated with (i) AldaraTM cream (5% w/w imiquimod) alone (ii) in combination with 
Dermapen (1000 µm) using the ‘poke-and-patch’ approach (iii)-(iv) in combination with 
Dermapen (1000 µm) using the ‘patch-and-poke’ approach  with different needle arrays. This 
resulted in improved drug delivery into the lower layer of the skin (dermis) with the ‘patch and 
poke’ strategy. 
 
Another possible limitation of the poke and patch approach with solid microneedles is limited drug 
flux from highly viscous formulations through microneedle perforated skin. This hypothesis was 
evaluated by Milewski et al. The group observed that as the viscosity of a formulation increases, 
the flux of naltrexone hydrochloride decreased across microneedle pretreated ex vivo mini-pig skin 
66. Pharmaceutical creams, such as AldaraTM (5%  w/w imiquimod) are inherently viscous 
formulations relative to gels and lotions 67. The rapid closure of microneedle channels coupled 
with slow permeation of the drug from the highly viscous AldaraTM cream into the skin may only 
limit the drug distribution into the stratum corneum with the poke-and-patch approach. 
Owing to the parallel detection capability, the ToF-SIMS data can simultaneously map the 
presence of excipients within biological tissues as well as the drug. One example of an excipient 
that is present in AldaraTM cream is isostearic acid. Conventionally, isostearic acid has been 
incorporated in various topical and cosmetic products as a permeation enhancer 68. However, 
Walter et al have shown that isostearic acid also displayed active pharmacological properties 
which are independent of the immune mediated response induced by imiquimod 69. Isostearic acid 
plays a critical role in inflammasome activation, which is pertinent for the overall efficacy of 
AldaraTM cream. It is also therefore of interest to chemically map the presence of isostearic acid in 
the microneedle channels. Through monitoring the molecular ion peak at m/z 285.3 indicated in 
Figure 4 (a), we were able to detect the co-localisation of the excipient within the microneedle 
channels as shown in Figure 4 (b) and (c). The peak assignment for isostearic acid was validated 
by referring to fragmentation pattern at m/z 285 with the reference spectra of pure isostearic acid 
on silicon wafer as shown in the supplementary data (Figure S3).
 
Figure 4. (a) Positive polarity ToF-SIMS spectra of ex vivo porcine skin treated with 5% w/w 
imiquimod topical cream using patch and poke approach, where the inset spectrum shows the 
peak of the [M+H]+ of imiquimod at m/z=241 and [M+H]+ of isostearic acid at m/z=285.3 (b) 
ToF-SIMS 2D chemical ion maps of phosphatidylcholine (biological tissue), imiquimod (active) 
and isostearic acid (excipient) acquired from cross section analysis of ex vivo porcine skin tissue 
after a 24 hour permeation experiment. Chemical ion map shows location of skin tissue along 
with the biodistribution of active and excipient. (c) an overlay image of the excipient isostearic 
acid marker (C18H37O2
+) in red, imiquimod (C14H17N4
+) in green and the skin marker 
(C5H15NPO4
+) in blue. The overlay indicates the ability ToF-SIMS to detect the colocalisation of 
imiquimod (active) and isostearic acid (excipient) within the microneedle channel within the ex 
vivo skin tissue. 
Traditional methods to study microneedle-enhanced permeation require the use of fluorescently-
labelled drug molecules to track the intradermal localisation of pharmaceuticals within the skin. 
This approach may alter the physiochemical properties of the drug leading to erroneous estimation 
of drug permeation into the skin 26. In addition, such methods only allow the tracking of the active 
drug molecule which limits our understanding of the dermal distribution of the other components 
in the formulation such as polymers and fatty acid-based surfactants.  The current work, highlights 
that the patch-and-poke strategy using oscillating solid microneedles may be a simple strategy to 
enable co-localised intradermal delivery of a poorly water soluble active and an excipient as 
evidenced by ToF-SIMS analysis. Similar to imiquimod, isostearic acid also has low water 
solubility which limits the penetration of the fatty acid into the more aqueous dermis 70. The co-
delivery of these compounds into the dermis ensures that isostearic acid may execute a synergistic 
action along with imiquimod in stimulating an effective inflammatory response for the treatment 
of nodular BCC. 
3.4.2 Effect of vibration on the delivery of imiquimod into the dermis using patch-and-poke 
approach with Dermapen 
 
One of the features of the Dermapen® is the vibration of microneedles at the tip of the device. This 
generates a stamp-like motion overcoming the issue of varying pressure of application by end-
users 71. Hence, we attempted to understand if vibration plays a functional role in the intradermal 
delivery of imiquimod using the patch and poke approach. We repeated the experiment using an 
ex vivo porcine skin permeation study followed by ToF-SIMS analysis of skin cross-section. As a 
comparator to the vibrating Dermapen®, we treated the skin with a DermastampTM. The 
DermastampTM perforates the skin in a single stamp motion without the assistance of a vibrating 
electric motor. Both microneedle devices used were 1000 µm in length. It can be seen from Figure 
5 that generation of imiquimod filled microneedle channels within the dermis with the patch-and-
poke strategy only occurred when the skin was treated with the oscillating Dermapen® following 
cream application.  
 
Figure 5. ToF-SIMS secondary ion distribution map of skin cross sections for ex vivo porcine 
skins that were treated with (i) Aldara cream (5% w/w imiquimod) followed by Dermapen® 
(1000 µm) application and (ii) Aldara cream (5% w/w imiquimod) application followed by  
1000 µm DermastampTM 
The ability of the Dermapen® to efficiently penetrate the skin relative to other microneedle systems 
is attributed to the vibrating-stamping motion of the device during device application 72,73. Izumi 
et al explored the effect of vibration on the penetration of microneedles into artificial silicone 
rubber skin. The group found that applying a vibration of 30 Hz to a microneedle array during skin 
insertion resulted in a reduction in the force needed to penetrate the skin 74. The reduction in 
puncture force is attributed to the reduction in frictional forces experienced by microneedles under 
vibration 75. The rapid vibration of the microneedles also mitigates the likelihood of viscoelastic 
materials such as skin and topical cream from attaching to the microneedle during the insertion 
step. This phenomenon provides an explanation as to why the patch-and-poke motion using 
DermastampTM was unsuccessful in delivering imiquimod into the dermis. The topical cream along 
with superficial skin tissues (i.e. stratum corneum) may attach to the tip of the needles during 
microneedle application resulting in poor penetration profile. Aoyagi et al also showed that that 
vibration indeed plays a critical role in microneedle insertion. However, Aoyagi and co-workers 
also demonstrated that a reduction in puncture force is also achievable when the skin is stretched 
prior to microneedle application 76. Unlike the DermastampTM, the presence of shoulders at the tip 
of microneedle cartridge of the Dermapen® generates tension on the skin during microneedle 
application. This helps to reduce the propensity of the skin to fold around the needles while 
decreasing the puncture force needed to perforate the skin. 
As it was apparent that the patch and poke approach using the Dermapen® provided the most 
effective intradermal delivery of imiquimod into skin, we then attempt to understand how 
imiquimod dermal distribution changes over 24 hours with this strategy. Subsequently, we 
repeated the ex vivo Franz cell permeation experiment using the patch-and-poke approach and 
performed ToF-SIMS analysis on the skin at five different time points. From Figure 6, we can see 
that using the patch-and-poke approach, the generation of imiquimod filled channels took place 
immediately (0 hours) post microneedle application on the skin after cream application. It is well 
known that the conventional poke-and-patch strategy is reliant on passive diffusion for the entry 
of drug molecules across aqueous microneedle channel to achieve intradermal delivery 66. Such a 
process is both slow and ineffective for the delivery of hydrophobic molecules due to their poor 
solubility in the aqueous channels. Coupled with the rapid closure of microneedle channels, this 
renders the poke-and-patch approach a poor strategy for the delivery of hydrophobic drugs. On the 
other hand, the patch-and-poke approach is dependent on the mechanical insertion of drug directly 
into the skin during microneedle application which overcomes the issues of solubility and pore 
closure. 
 
Figure 6. ToF-SIMS secondary ion distribution map of porcine skin cross sections from different time 
points. This highlights improved drug delivery into the lower layer of the skin (dermis) that persisted in 
the skin up to 24 hours. In addition, the formulation was immediately present in the deeper layers of the 
skin upon microneedle application. Phosphatidylcholine highlights the viable epidermis and dermis while 
ceramide highlights the top layer of the skin. Black circles indicate areas filled by hair follicles. 
The presence of imiquimod loaded channels within the dermis that persisted for 24 hours was 
attributed to the poor water solubility of the drug 77. The limited water solubility of imiquimod 
coupled with the fact that the water composition increases with dermal depth serves as possible 
explanation as to why imiquimod channels remained in the ex vivo skin tissues up to 24 hours 78. 
The application of imiquimod cream followed by Dermapen® application generates localised 
 32 
regions of imiquimod within the skin which resemble the structure of the microneedle channels. 
This shows that using a patch-and-poke strategy with oscillating microneedles provide an elegant 
synergy of existing products to enhance localisation of imiquimod intradermally. Such a drug 
delivery strategy may help prevent the requirement for surgical intervention for the treatment of 
deep-rooted basal cell carcinoma.  
4. Conclusion 
This work expands current understanding on the application of solid microneedles as a physical 
permeation enhancement strategy to promote the delivery of imiquimod into the skin for the 
treatment for BCC. The approach in which microneedles are used in combination with Aldara™ 
cream plays a critical role for the successful intradermal delivery of imiquimod into the skin. It 
has been demonstrated that in order to successfully deliver a hydrophobic molecule such as 
imiquimod into the dermis, a patch-and-poke approach is superior to the conventional poke-and-
patch approach. Furthermore, it has also been demonstrated that an oscillating microneedle system, 
such as the Dermapen® for the patch-and-poke strategy, is a critical factor in providing successful 
intradermal delivery of imiquimod into the skin. Using this novel patch-and-poke approach 
hydrophobic drugs are mechanically inserted into the microneedle channels within the dermis upon 
microneedle application. This avoids the generation of hydrophilic/aqueous microneedle channels 
formed using the traditional poke-and-patch which can pose as a barrier to drug permeation. In 
summary, this work suggests that the combination of AldaraTM cream in combination with the 
oscillating Dermapen® provides an elegant synergy to enhance localised intradermal delivery of 
imiquimod. Such a strategy may provide a less invasive intervention to patients who would prefer 
an alternative treatment to surgery for the treatment of nodular BCC.     
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Supporting Information is available free of charge at the ACS website:- 
 Dye binding and histology study, HPLC analysis of imiquimod concentration in receptor fluid 
post-permeation study expressed as concentration (µg/ml), Isostearic acid peak assignment and 
validation. 
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